LEXINGTON, Mass.--(BUSINESS WIRE)--Imprivata® (NYSE: IMPR), the healthcare IT security company, today announced financial results for the fourth quarter and full year of fiscal 2014. Revenues for the fourth quarter were $29.0 million, an increase of 34% from revenues of $21.6 million for the same period in 2013. Revenues for the twelve months ended December 31, 2014 were $97.0 million, an increase of 36% from revenues of $71.1 million for the same period in 2013.
“Our record fourth quarter was a great end to what was a very successful year for Imprivata. We were able to broaden our product portfolio while continuing to execute and expand our core market,” said Omar Hussain, president and CEO of Imprivata. “Imprivata OneSign, Imprivata Cortext, and Imprivata Confirm ID, along with other products in our development pipeline, will continue to build on Imprivata’s reputation as a healthcare IT security leader. I believe we are very well positioned as we execute our growth strategy in 2015 and beyond.”
Net loss for the fourth quarter of 2014 was $1.7 million, or $(0.07) per basic and diluted share attributable to common stockholders, as compared to a net loss of $3.3 million, or $(1.26) per basic and diluted share attributable to common stockholders for the same period in 2013. Net loss for the twelve months ended December 31, 2014 was $16.7 million, or $(1.37) per basic and diluted share attributable to common stockholders, as compared to a net loss of $5.5 million, or $(3.12) per basic and diluted share attributable to common stockholders for the same period in 2013.
Jeff Kalowski, CFO of Imprivata, commented, “We are pleased that our continued investments in sales, marketing, research and development continue to grow our top line revenue and enhance our product offerings. Additionally, our strategic investments are allowing Imprivata to capture additional market share, as we continue to bolster our overall market leadership position.”
Adjusted EBITDA(1) for the fourth quarter of 2014 was a loss of $34,000, as compared to a loss of $2.4 million for the same period in 2013. Non-GAAP net loss (2) for the fourth quarter of 2014 was $1.0 million, or $(0.04) per basic and diluted share, as compared to non-GAAP net loss of $3.0 million, or $(0.84) per basic share and diluted share, for the same period in 2013. Adjusted EBITDA for the twelve months ended December 31, 2014 was a loss of $11.5 million, as compared to a loss of $3.4 million for the same period in 2013. Non-GAAP net loss for the twelve months ended December 31, 2014 was $15.0 million, or $(1.08) per basic and diluted share, as compared to non-GAAP net loss of $5.2 million, or $(1.56) per basic and diluted share, for the same period in 2013. A reconciliation of GAAP to these non-GAAP financial measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”
| (1) | Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization adjusted for foreign currency gains (losses), stock based-compensation and the impact of the fair value revaluation on our contingent liability. | |||
| (2) | Non-GAAP net income (loss) and non-GAAP net income (loss) per share excludes amortization of purchased intangible assets, stock-based compensation and the impact of the fair value revaluation on our contingent liability. | |||
First Quarter and Full-Year 2015 Financial Outlook
For the full-year, we expect revenue between $120.0 million and $122.0 million and Adjusted EBITDA to be between a loss of $7.9 million and $6.6 million. In terms of earnings per share, we expect GAAP loss to be between $0.58 per share and $0.52 per share and non-GAAP loss, which adjusts for stock-based compensation, amortization of purchased intangible assets and the contingent liability revaluation, to be between $0.49 per share and $0.45 per share. Our annual EPS estimates are based on an estimated weighted average-share count of 24.0 million.
For the first quarter, we expect revenue between $24.0 million and $24.5 million and Adjusted EBITDA to be between a loss of $6.6 million and $6.3 million. In terms of earnings per share, we expect GAAP loss to be approximately $0.34 per share or $0.33 per share and non-GAAP loss, which adjusts for stock-based compensation, amortization of purchased intangible assets and the contingent liability revaluation, to be approximately $0.32 per share or $0.31 per share. Our annual EPS estimates are based on an estimated weighted average-share count of 23.7 million.
Conference Call Information
Imprivata management will host a conference call at 5:00 pm (Eastern Time) on Tuesday, February 24, 2015 to discuss the Company’s fourth quarter and full year ended December 31, 2014 results, its business outlook and other matters. The conference call will be accessible by dialing 719-325-2376 or 888-417-8516 for international callers, and referencing conference ID number 1796517. A live webcast of the conference call will also be available on the investor relations section of the company’s website at http://investor.imprivata.com/.
An audio replay of the conference call will be available approximately one hour after conclusion of the call and will be accessible through March 10, 2015. The replay can be accessed by dialing 888-203-1112, or 719-457-0820 for international callers, and providing access code 1796517.
About Imprivata
Imprivata, Inc. (NYSE: IMPR) headquartered in Lexington, Massachusetts, a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit www.imprivata.com.
All Imprivata products are trademarks of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our customer base and our overall business, our market opportunity, our goal to maintain market leadership and our expected financial results for Q1 2015 and the full fiscal year 2015. All statements other than statements of historical fact contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “could,” “increases,” “improves,” “reduces,” “implements,” “results,” “addresses,” or the negative of these terms or other comparable terminology. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Imprivata’s control. Imprivata’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, our ability to successfully develop and introduce new solutions and products for existing solutions; our ability to attract new customers and retain and increase sales to existing customers; developments in the healthcare industry or regulatory environment; seasonal variations in the purchasing patterns of our customers; the lengthy and unpredictable sales cycles for new customers; our ability to maintain successful relationships with our channel partners and technology alliance partners; our dependency on sole source suppliers and a contract manufacturer for hardware components of our Imprivata OneSign solution; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of protected health information; our ability to protect our intellectual property rights, and the other risks detailed in Imprivata’s risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to Imprivata’s Registration Statement on Form S-1 declared effective by the SEC on June 24, 2014, as well as other documents that may be filed by Imprivata from time to time with the SEC. The forward-looking statements included in this press release represent Imprivata’s views as of the date of this press release. Imprivata undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Non-GAAP Financial Measures
Imprivata has provided in this release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA, non-GAAP net income (loss) and non-GAAP net income (loss) per share. These non-GAAP financial measures are not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Imprivata believes that the use of these non-GAAP financial measures provides supplementary information for investors to use in evaluating operating performance and in comparing its financial measures with other companies in Imprivata's industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA (EBITDA adjusted for foreign currency gains (losses), stock based-compensation and the impact of the fair value revaluation on our contingent liability), non-GAAP net income (loss) and non-GAAP net income (loss) per share exclude amortization expense associated with our purchased intangible assets, stock-based compensation and the impact of the re-measurement to fair value of our contingent liability. Non-GAAP financial measures that Imprivata uses may differ from measures that other companies may use. These non-GAAP financial measures disclosed by Imprivata are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.
|
Imprivata, Inc. |
||||||||||||||||
|
Condensed Consolidated Statements of Operations |
||||||||||||||||
|
(in thousands, except per share amounts) |
||||||||||||||||
|
(unaudited) |
||||||||||||||||
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Revenue | ||||||||||||||||
| Product | $ | 16,532 | $ | 12,201 | $ | 52,164 | $ | 39,124 | ||||||||
| Maintenance and services | 12,496 | 9,433 | 44,815 | 31,987 | ||||||||||||
| Total revenue | 29,028 | 21,634 | 96,979 | 71,111 | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Product | 3,388 | 2,926 | 12,310 | 7,849 | ||||||||||||
| Maintenance and services | 4,732 | 3,495 | 17,678 | 11,020 | ||||||||||||
| Total cost of revenue | 8,120 | 6,421 | 29,988 | 18,869 | ||||||||||||
| Gross Profit | 20,908 | 15,213 | 66,991 | 52,242 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 6,529 | 6,233 | 25,781 | 19,609 | ||||||||||||
| Sales and marketing | 12,239 | 9,711 | 45,003 | 30,538 | ||||||||||||
| General and administrative | 3,566 | 2,483 | 12,052 | 7,619 | ||||||||||||
| Total operating expenses | 22,334 | 18,427 | 82,836 | 57,766 | ||||||||||||
| Loss from operations | (1,426 | ) | (3,214 | ) | (15,845 | ) | (5,524 | ) | ||||||||
| Other (expense) income | ||||||||||||||||
| Foreign currency exchange (loss) gain | (169 | ) | (63 | ) | (576 | ) | 229 | |||||||||
| Interest and other (expense) income, net | (18 | ) | 52 | (146 | ) | (120 | ) | |||||||||
| Loss before income taxes | (1,613 | ) | (3,225 | ) | (16,567 | ) | (5,415 | ) | ||||||||
| Income taxes | 50 | 34 | 169 | 108 | ||||||||||||
| Net loss | $ | (1,663 | ) | $ | (3,259 | ) | $ | (16,736 | ) | $ | (5,523 | ) | ||||
| Accretion of preferred stock | - | (1,238 | ) | (2,442 | ) | (4,952 | ) | |||||||||
| Net loss attributable to common shareholders | $ | (1,663 | ) | $ | (4,497 | ) | $ | (19,178 | ) | $ | (10,475 | ) | ||||
| Net loss per share attributable to common stockholders | ||||||||||||||||
| Basic and diluted | $ | (0.07 | ) | $ | (1.26 | ) | $ | (1.37 | ) | $ | (3.12 | ) | ||||
|
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders |
||||||||||||||||
| Basic and diluted | 23,730 | 3,570 | 13,950 | 3,359 | ||||||||||||
|
Imprivata, Inc. |
||||||||
|
Condensed Consolidated Balance Sheets |
||||||||
|
(in thousands) |
||||||||
|
(unaudited) |
||||||||
| December 31, | ||||||||
| 2014 | 2013 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 78,524 | $ | 13,284 | ||||
| Accounts receivable, net of allowances | 25,335 | 19,754 | ||||||
| Prepaid expenses and other current assets | 3,516 | 2,541 | ||||||
| Total current assets | 107,375 | 35,579 | ||||||
| Property and equipment, net | 7,640 | 6,682 | ||||||
| Goodwill | 1,560 | 1,560 | ||||||
| Intangible assets, net | 1,499 | 2,000 | ||||||
| Other assets | 105 | 649 | ||||||
| Total Assets | $ | 118,179 | $ | 46,470 | ||||
|
Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) |
||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,498 | $ | 3,586 | ||||
| Accrued expenses and other current liabilities | 10,565 | 9,149 | ||||||
| Current portion of capital lease obligations and long-term debt | 625 | 313 | ||||||
| Current portion of other long-term liabilities | 288 | 249 | ||||||
| Current portion of deferred revenue | 33,120 | 25,084 | ||||||
| Current portion of contingent purchase price liability | 152 | — | ||||||
| Total current liabilities | 47,248 | 38,381 | ||||||
| Deferred revenue, net of current portion | 4,021 | 3,490 | ||||||
|
Capital lease obligations, long-term debt and royalty obligations, net of current portion |
619 | 410 | ||||||
| Other long-term liabilities, net of current portion | 1,535 | 1,181 | ||||||
| Contingent purchase price liability, net of current portion | 480 | 1,008 | ||||||
| Total liabilities | 53,903 | 44,470 | ||||||
| Commitments and contingencies | ||||||||
| Redeemable convertible preferred stock |
— |
91,607 | ||||||
| Stockholders' equity (deficit): | ||||||||
| Undesignated preferred stock | — | |||||||
| Common stock | 24 | 4 | ||||||
| Additional paid-in capital | 171,903 |
— |
||||||
| Accumulated other comprehensive loss | (100 | ) | (145 | ) | ||||
| Accumulated deficit | (107,551 | ) | (89,466 | ) | ||||
| Total stockholders' equity (deficit) | 64,276 | (89,607 | ) | |||||
|
Total Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) |
$ | 118,179 | $ | 46,470 | ||||
|
Imprivata, Inc. |
||||||||
|
Condensed Consolidated Statements of Cash Flows |
||||||||
|
(in thousands) |
||||||||
|
(unaudited) |
||||||||
|
Twelve Months Ended |
||||||||
| 2014 | 2013 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (16,736 | ) | $ | (5,523 | ) | ||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| Depreciation and amortization expense | 3,075 | 2,397 | ||||||
| Provision for doubtful accounts and sales allowance | 99 | 61 | ||||||
| Stock-based compensation | 1,612 | 640 | ||||||
| Loss on disposal of fixed assets | 75 | 80 | ||||||
| Change in value of contingent purchase price liability | (376 | ) | (877 | ) | ||||
| Changes in operating assets and liabilities | ||||||||
| Accounts receivable | (5,680 | ) | (3,248 | ) | ||||
| Prepaid expenses and other current assets | (593 | ) | (1,124 | ) | ||||
| Other assets | (7 | ) | (6 | ) | ||||
| Deferred revenue | 8,567 | 6,818 | ||||||
| Accounts payable | (1,010 | ) | 47 | |||||
| Accrued expenses and other current liabilities | 2,689 | 1,836 | ||||||
| Other liabilities | 185 | (353 | ) | |||||
| Net cash (used in) provided by operating activities | (8,100 | ) | 748 | |||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (3,187 | ) | (3,413 | ) | ||||
| Restricted cash | - | 97 | ||||||
| Net cash used in investing activities | (3,187 | ) | (3,316 | ) | ||||
| Cash flows from financing activities: | ||||||||
|
Proceeds from initial public offering, net of underwriting discounts and commissions |
80,213 | - | ||||||
| Deferred offering costs | (3,405 | ) | (20 | ) | ||||
| Repayments for capital lease obligations, long-term debt and other | (674 | ) | (317 | ) | ||||
| Proceeds from exercise of stock options | 476 | 916 | ||||||
| Net cash provided by financing activities | 76,610 | 579 | ||||||
| Effect of exchange rates on cash and cash equivalents | (83 | ) | (137 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 65,240 | (2,126 | ) | |||||
| Cash and cash equivalents, beginning of year | 13,284 | 15,410 | ||||||
| Cash and cash equivalents, end of year | $ | 78,524 | $ | 13,284 | ||||
|
Imprivata, Inc. |
||||||||||||||||
|
Non-GAAP Financial Measures |
||||||||||||||||
|
(in thousands, except per share amounts) |
||||||||||||||||
|
(unaudited) |
||||||||||||||||
| Reconciliation of GAAP Net Loss to Adjusted EBITDA | ||||||||||||||||
|
Three Months |
Twelve Months |
|||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| GAAP net loss | $ | (1,663 | ) | $ | (3,259 | ) | $ | (16,736 | ) | $ | (5,523 | ) | ||||
| Adjustments to reconcile to Adjusted EBITDA: | ||||||||||||||||
| Income tax expense | 50 | 34 | 169 | 108 | ||||||||||||
| Depreciation and amortization | 834 | 650 | 3,075 | 2,397 | ||||||||||||
| Other expense (income), net | 187 | 11 | 722 | (109 | ) | |||||||||||
| Stock-based compensation | 486 | 231 | 1,612 | 640 | ||||||||||||
| Change in fair value of contingent liability | 72 | (93 | ) | (376 | ) | (877 | ) | |||||||||
| Adjusted EBITDA | $ | (34 | ) | $ | (2,426 | ) | $ | (11,534 | ) | $ | (3,364 | ) | ||||
| Reconciliation of GAAP Net Loss to Non-GAAP Net Loss and Non-GAAP Net Loss Per Share (a) | ||||||||||||||||
|
Three Months |
Twelve Months |
|||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| GAAP net loss | $ | (1,663 | ) | $ | (3,259 | ) | $ | (16,736 | ) | $ | (5,523 | ) | ||||
| Adjustments to reconcile to Non-GAAP net income: | ||||||||||||||||
| Amortization of purchased intangible assets | 116 | 128 | 501 | 521 | ||||||||||||
| Stock-based compensation | 486 | 231 | 1,612 | 640 | ||||||||||||
| Change in fair value of contingent liability | 72 | (93 | ) | (376 | ) | (877 | ) | |||||||||
| Non-GAAP net loss | $ | (989 | ) | $ | (2,993 | ) | $ | (14,999 | ) | $ | (5,239 | ) | ||||
| Non-GAAP net loss per share | ||||||||||||||||
| Basic and diluted | $ | (0.04 | ) | $ | (0.84 | ) | $ | (1.08 | ) | $ | (1.56 | ) | ||||
|
Weighted average common shares outstanding used in computing non-GAAP net loss per share |
||||||||||||||||
| Basic and diluted | 23,730 | 3,570 | 13,950 | 3,359 | ||||||||||||
|
(a) The Company reconciles non-GAAP net loss per share beginning with GAAP net loss instead of GAAP net loss attributable to common stockholders in order to eliminate the effect of the accretion of preferred stock on the calculation. |
